论文部分内容阅读
目的探讨肝复片联合拉米夫定治疗慢性乙型肝炎的临床疗效。方法 1997年12月～2003年10月在本院治疗的152例慢性乙型肝炎患者,按随机配对原则,分为单用拉米夫定对照组与肝复片联合拉米夫定治疗组,每组均为76例,两组具有可比性,疗程12个月。结果两组患者疗效比较,差异有统计学意义(p<0.01);治疗后6、12个月,两组患者HBeAg转阴率进行χ2检验,差异有统计学意义(p<0.05);治疗后3、6、12个月,两组患者HBV DNA转阴率进行χ2检验,差异有统计学意义(p<0.05);治疗后1、3个月,两组患者ALT、AST复常率进行χ2检验,差异有统计学意义(p<0.05)。结论肝复片联合拉米夫定治疗慢性乙型肝炎,具有增强抗乙型肝炎病毒能力、保护肝功能、促进肝脏炎症消失等作用。
Objective To investigate the clinical efficacy of Ganpian combined with lamivudine in the treatment of chronic hepatitis B. Methods A total of 152 chronic hepatitis B patients treated in our hospital from December 1997 to October 2003 were randomly divided into three groups: lamivudine alone group and lamivudine plus lamivudine group, Each group was 76 cases, two groups were comparable, treatment of 12 months. Results The curative effect of the two groups was statistically significant (p <0.01). After 6 and 12 months of treatment, the HBeAg negative rates of the two groups were tested byχ2 test, the difference was statistically significant (p <0.05); after treatment At 3, 6 and 12 months, the rates of HBV DNA negative conversion in the two groups were analyzed by χ2 test, the difference was statistically significant (p <0.05). At 1 and 3 months after treatment, the ALT and AST recovery rates in both groups were χ2 Test, the difference was statistically significant (p <0.05). Conclusions GCP plus lamivudine treatment of chronic hepatitis B can enhance the ability of anti-hepatitis B virus, protect liver function and promote the disappearance of liver inflammation.